Role of Collagen Conduit With Duloxetine and/or Pregabalin in the Management of Partial Peripheral Nerve Injury

Khan, Junad; Alghamdi, Hamed A.; Anwer, Muhammad Moin; Eliav, Eli; Ziccardi, Vincent B.

doi:10.1016/j.joms.2016.01.022

Cited by 11 publications

(6 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we demonstrated a significant inhibitory effect of PGB on cytokines secretion in vivo, and in splenocytes but www.nature.com/scientificreports www.nature.com/scientificreports/ not in PMs in vitro. Whilst our data were similar to previous reports in the inhibition of IL-6, IL-1β and TNF-α secretion 19,[38][39][40][41] , careful comparisons should be applied as those reports used different mitogens (carrageenan) 19 , different doses of PGB (at least 30 mg/kg of PGB) 19 , different inflammatory models (hyperglycemic stroke 39 or chronic constriction injury models 40,41 ), different sample for the assessment of cytokines levels (brain tissue 39 or nerve tissue 40,41 ) or even different animal species (rat) 19,[38][39][40][41] . Noteworthy, species, strain-and sex-associated differences in the regulation of some immune responses have been previously reported and similarity in responses is dependent on the outcomes measured [42][43][44][45] .…”

Section: Discussionsupporting

confidence: 93%

Pregabalin inhibits in vivo and in vitro cytokine secretion and attenuates spleen inflammation in Lipopolysaccharide/Concanavalin A -induced murine models of inflammation

Abu-rish

Mansour

et al. 2020

Sci Rep

View full text Add to dashboard Cite

is observed in the principal PGB-indicated conditions which share the alteration in IL-6, TNF-α, IL-2 and IL-1β cytokines level. Yet, reports on PGB immunomodulatory and anti-inflammatory effects are a few and focused mainly on in vitro assays, local inflammatory changes within the nervous system, and attenuation of the secretion of only IL-1β and TNF-α cytokines 18-20. In addition, PGB effects on cytokines secretion in immune cells, such as isolated splenocytes and peritoneal macrophages (PMs), and its effect on lymphoid organs, were not examined before. Therefore, there is a need to perform a simultaneous assessment of the effect of PGB on the secretion of the cytokines that were commonly elevated in the aforementioned PGB-indicated conditions (IL-6, TNF-α, IL-1β and IL-2) and to expand the investigation to its effect on lymphoid organs and cytokine secretion in immune cells. As peripheral inflammation and elevated systemic cytokines levels were demonstrated in the above-mentioned PGB-indicated conditions, we investigated in this study the effect of PGB on murine models of peripheral inflammation. In this study, we used for the first time, LPS and ConA-induced murine models of inflammation to examine the effect of PGB on peripheral proinflammatory cytokine secretion (IL-6, TNF-α, IL-1β and IL-2) in vitro and in vivo in BALB/c mice. LPS-model of inflammation has been employed before to study neuroinflammatory conditions, seizure and anxiety disorders in mice 21-25 , while ConA was used to investigate T-cell function in patients with fibromyalgia 26. Additionally, in this study, the effect of PGB on mitogen-induced inflammatory changes in the spleen, as a lymphoid organ, was also examined for the first time. Regarding in vitro investigation, the lack of reports that examined the effect of PGB on the secretion of cytokines in immune cells prompted us to investigate such effects of PGB on basal and mitogen-induced proinflammatory cytokines secretion in splenocytes and peritoneal macrophages (PMs).

show abstract

Section: Discussionsupporting

confidence: 93%

Pregabalin inhibits in vivo and in vitro cytokine secretion and attenuates spleen inflammation in Lipopolysaccharide/Concanavalin A -induced murine models of inflammation

Abu-rish

Mansour

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…According to the BMI in GSE135917, both OSA and control samples were obese and under chronic inflammation, which may affect the expressions of IL6. Besides, we also found that some of OSA and control individuals were taking medicines, such as duloxetine, insulin and vitamin D, which may either elevate or reduce the expression of IL6 ( 32 – 34 ). Those characteristics of OSA and control samples used in the current study may cause the conflicted results with previous finding.…”

Section: Discussionmentioning

confidence: 75%

The Discovery, Validation, and Function of Hypoxia-Related Gene Biomarkers for Obstructive Sleep Apnea

Pan

Liu

et al. 2022

Front. Med.

View full text Add to dashboard Cite

While there is emerging evidence that hypoxia critically contributes to the pathobiology of obstructive sleep apnea (OSA), the diagnostic value of measuring hypoxia or its surrogates in OSA remains unclear. Here we investigated the diagnostic value of hypoxia-related genes and explored their potential molecular mechanisms of action in OSA. Expression data from OSA and control subjects were downloaded from the Gene Expression Omnibus database. Differentially-expressed genes (DEGs) between OSA and control subjects were identified using the limma R package and their biological functions investigated with the clusterProfiler R package. Hypoxia-related DEGs in OSA were obtained by overlapping DEGs with hypoxia-related genes. The diagnostic value of hypoxia-related DEGs in OSA was evaluated by receiver operating curve (ROC) analysis. Random forest (RF) and lasso machine learning algorithms were used to construct diagnostic models to distinguish OSA from control. Geneset enrichment analysis (GSEA) was performed to explore pathways related to key hypoxia-related genes in OSA. Sixty-three genes associated with hypoxia, transcriptional regulation, and inflammation were identified as differentially expressed between OSA and control samples. By intersecting these with known hypoxia-related genes, 17 hypoxia-related DEGs related to OSA were identified. Protein-protein interaction network analysis showed that 16 hypoxia-related genes interacted, and their diagnostic value was further explored. The 16 hypoxia-related genes accurately predicted OSA with AUCs >0.7. A lasso model constructed using AREG, ATF3, ZFP36, and DUSP1 had a better performance and accuracy in classifying OSA and control samples compared with an RF model as assessed by multiple metrics. Moreover, GSEA revealed that AREG, ATF3, ZFP36, and DUSP1 may regulate OSA via inflammation and contribute to OSA-related cancer risk. Here we constructed a reliable diagnostic model for OSA based on hypoxia-related genes. Furthermore, these transcriptional changes may contribute to the etiology, pathogenesis, and sequelae of OSA.

show abstract

“…On the other hand, another study of pregabalin 10 mg/kg over three weeks did not find an effect on nerve regeneration [60]. A third study found that pregabalin-collagen therapy after injury aided in nerve regeneration by inhibiting IL-10 release, a pro-inflammatory cytokine that negatively impacts the healing processes [61]. Our current study does not provide information on the effects of pregabalin on corneal nerve regeneration and as such, future studies are needed that focus on these connections, such as with the use of confocal microscopy.…”

Section: Discussionmentioning

confidence: 99%

Pregabalin Failed to Prevent Dry Eye Symptoms after Laser-Assisted in Situ Keratomileusis (LASIK) in a Randomized Pilot Study

Patel

Small

Troyo

et al. 2019

JCM

View full text Add to dashboard Cite

Purpose: Perioperative pregabalin administration has been found to reduce the risk of persistent pain after a variety of surgical procedures. However, this approach has not been tested in relation to eye surgery. As such, the purpose of this study was to evaluate whether perioperative pregabalin can reduce the presence of dry eye (DE) symptoms, including eye pain, six months after laser-assisted in situ keratomileusis (LASIK). Methods: Prospective, masked, randomized single-center pilot study. Patients were treated with either pregabalin (oral solution of pregabalin 150 mg twice daily, first dose prior to surgery, continued for a total of 28 doses over 14 days) or placebo solution. The primary outcome was dry eye symptoms as measured by the Dry Eye Questionnaire 5 (DEQ-5). Secondary outcome measures included pain-related eye symptoms. Results: In total, 43 individuals were enrolled in the study and randomized to pregabalin (n = 21) or placebo (n = 22). Of those, 42 individuals completed the final visit after six months of follow-up. Some differences were noted between the two groups at baseline, including a higher frequency of females in the pregabalin group. At 6-months, there were no significant differences in the percentage of patients with DE symptoms (DEQ5 ≥ 6, 57% vs. 33%, p = 0.14), DE symptom severity (DEQ5, 6.6 ± 5.0 vs. 4.5 ± 4.2, p = 0.14), ocular pain intensity (numerical rating scale, 1.10 ± 1.48 vs. 0.38 ± 0.97, p = 0.08), or neuropathic pain complaints (Neuropathic Pain Symptom Inventory-Eye, 2.81 ± 4.07 vs. 3.14 ± 5.85, p = 0.83) between the pregabalin and control groups. Ocular signs were likewise similar between the groups, and of note, did not correlate with DE symptoms. The strongest predictor of DE symptoms six months post-surgery was the presence of DE symptoms prior to surgery. Conclusions: Perioperative pregabalin did not reduce the frequency or severity of DE symptoms at a six month follow-up after LASIK in this small pilot study.

show abstract

Role of Collagen Conduit With Duloxetine and/or Pregabalin in the Management of Partial Peripheral Nerve Injury

Abstract: Using a collagen conduit and duloxetine, pregabalin, and their combination helped alleviate neuropathic pain. The mechanism of action might be associated, at least in part, to cytokines.

Cited by 11 publications

References 49 publications

Pregabalin inhibits in vivo and in vitro cytokine secretion and attenuates spleen inflammation in Lipopolysaccharide/Concanavalin A -induced murine models of inflammation

Pregabalin inhibits in vivo and in vitro cytokine secretion and attenuates spleen inflammation in Lipopolysaccharide/Concanavalin A -induced murine models of inflammation

The Discovery, Validation, and Function of Hypoxia-Related Gene Biomarkers for Obstructive Sleep Apnea

Pregabalin Failed to Prevent Dry Eye Symptoms after Laser-Assisted in Situ Keratomileusis (LASIK) in a Randomized Pilot Study

Contact Info

Product

Resources

About